See All Slides - tctmd.com

Slides

Presentation Cell Therapy 2013

Microvascular Obstruction, Infarct Size, and LV Remodeling

Presenter: Andreas M. Zeiher

January 23, 2013

Presentation Cell Therapy 2013

Sitagliptin plus Granulocyte-Colony Stimulating Factor in Acute Myocardial Infarction

Presenter: Wolfgang-Michael Franz

January 22, 2013

Presentation Cell Therapy 2013

Swiss AMI Study: Long-term Findings

Presenter: Daniel S?rder

January 22, 2013

Presentation

Same-Day Discharge Compared with Overnight Hospitalization After Uncomplicated PCI

Presenter: E. Abdelaal

January 22, 2013

Presentation Cell Therapy 2013

CD-34+ Cells for Ischemic Heart Failure

Presenter: Bojan Vrtovec

January 22, 2013

Presentation Cell Therapy 2013

TIME: CCTRN Study of Bone Marrow-Derived Stem Cells Following STEMI

Presenter: Jay H. Traverse

January 22, 2013

Presentation Cell Therapy 2013

Cardiac-derived Stem Cells Post-MI: CADUCEUS and ALLSTAR

Presenter: Eduardo Marb?n

January 22, 2013

Presentation Cell Therapy 2013

Clinical Outcomes and Surrogate Efficacy Data for a Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells (Revascor™) in Patients With Chronic Heart Failure of Ischemic or Nonischem

Presenter: Kenneth M. Borow

January 22, 2013

Presentation Cell Therapy 2013

AMR-001 Phase 1 Outcome and PreSERVE Study Design: Autologous CD34+ Cells

Presenter: Jonathan Sackner-Bernstein

January 22, 2013

Presentation Cell Therapy 2013

A Phase 2 Pilot Study to Evaluate the Safety and Activity of BB3 as an Adjunct to PCI in Subjects Presenting with STEMI

Presenter: Frank J. Giordano

January 22, 2013

Advertisement

Slides

Microvascular Obstruction, Infarct Size, and LV Remodeling

Sitagliptin plus Granulocyte-Colony Stimulating Factor in Acute Myocardial Infarction

Swiss AMI Study: Long-term Findings

Same-Day Discharge Compared with Overnight Hospitalization After Uncomplicated PCI

CD-34+ Cells for Ischemic Heart Failure

TIME: CCTRN Study of Bone Marrow-Derived Stem Cells Following STEMI

Cardiac-derived Stem Cells Post-MI: CADUCEUS and ALLSTAR

Clinical Outcomes and Surrogate Efficacy Data for a Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells (Revascor™) in Patients With Chronic Heart Failure of Ischemic or Nonischem

AMR-001 Phase 1 Outcome and PreSERVE Study Design: Autologous CD34+ Cells

A Phase 2 Pilot Study to Evaluate the Safety and Activity of BB3 as an Adjunct to PCI in Subjects Presenting with STEMI

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content